L-SPD, as an antipsychotic medication, has a D1R agonist/D2R antagonist pharmacological profile and relieves symptoms of schizophrenia through D2 receptor inhibition in NAc and D1 receptor activation in PFC. This evidence concerns the gene DRD1 and schizophrenia.